Botanix Pharmaceuticals Company Description
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States.
Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis.
Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.
| Country | Australia |
| Founded | 1984 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Howie McKibbon |
Contact Details
Address: 41 – 47 Colin Street West Perth, 6005 Australia | |
| Phone | 61 8 6555 2945 |
| Website | botanixpharma.com |
Stock Details
| Ticker Symbol | BXPHF |
| Exchange | OTCMKTS |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000BOT2 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Howie McKibbon | Chief Executive Officer |
| Vincent P. Ippolito | MD and Executive Chairman |
| Graeme Morissey | Chief Financial Officer |
| Dr. Patricia S. Walker M.D., Ph.D. | Chief Medical Adviser |
| Dr. Boris Meyerson Ph.D. | Chief Business Officer |
| David Morgan | Head of Corporate Affairs |
| Kevin Wojciechowski | Head of HCP Marketing and Sales Training |
| Susan Patricia Park A.C.A., A.C.I.S., ACSA, AGIA, B.Com., C.A., F Fin | Company Secretary |
| Darin Van Arsdale | Director of Sales Operations |